Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A round brings $60mm to 89bio

Executive Summary

Launched with small molecules licensed from Teva, 89bio (developing treatments for liver and metabolic diseases) concurrently raised $60mm through its Series A round. Founding investors OrbiMed Israel and OrbiMed US led the round and were joined by Longitude Capital, RA Capital Management, and Pontifax.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies